Tags

Type your tag names separated by a space and hit enter

Immunogenicity and safety of a China-made monovalent pandemic (H1N1) 2009 influenza A vaccine in healthcare workers in Guangzhou, China.
Jpn J Infect Dis. 2011; 64(3):190-4.JJ

Abstract

Because healthcare workers played an important role in the battle against novel pandemic (H1N1) 2009 influenza, a clinical study was conducted to examine the immunogenicity and safety of a single dose of a China-made monovalent, split-virus, pandemic (H1N1) 2009 influenza vaccine in this special high-risk population. Healthcare workers in the First Affiliated Hospital of Guangzhou Medical College who received the pandemic (H1N1) 2009 influenza vaccine were prospectively enrolled. Antibody titers were measured at enrollment and 14 days later using hemagglutination-inhibition (HI) and microneutralization assays. Adverse events were recorded within 7 days and 6 months after vaccination. Double sera were provided by 51 of 65 enrolled subjects. Postvaccination titers of 1:40 or more on HI assay were observed in 96% of recipients. Seroconversion or a significant increase in titer on HI assay occurred in 59% of subjects. The factor increase in GMTs was 4.3. The majority of complaints were mild to moderate in intensity. Although more than half of healthcare workers seemed immune to the pandemic (H1N1) influenza A virus before vaccination, most of the subjects still showed a fast, robust immune response to a single 15-μg dose of a monovalent, split-virus unadjuvanted pandemic H1N1 2009 influenza vaccine.

Authors+Show Affiliations

Department of Respiratory Medicine of the First Affiliated Hospital of Guangzhou Medical College, State Key Laboratory of Respiratory Disease (Guangzhou Medical University), Guangzhou, P.R. China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21617301

Citation

Zhan, Yangqing, et al. "Immunogenicity and Safety of a China-made Monovalent Pandemic (H1N1) 2009 Influenza a Vaccine in Healthcare Workers in Guangzhou, China." Japanese Journal of Infectious Diseases, vol. 64, no. 3, 2011, pp. 190-4.
Zhan Y, Yang Z, Li L, et al. Immunogenicity and safety of a China-made monovalent pandemic (H1N1) 2009 influenza A vaccine in healthcare workers in Guangzhou, China. Jpn J Infect Dis. 2011;64(3):190-4.
Zhan, Y., Yang, Z., Li, L., Ye, D., Wu, H., Fu, R., Zhao, S., Wang, Y., Zhou, R., & Chen, R. (2011). Immunogenicity and safety of a China-made monovalent pandemic (H1N1) 2009 influenza A vaccine in healthcare workers in Guangzhou, China. Japanese Journal of Infectious Diseases, 64(3), 190-4.
Zhan Y, et al. Immunogenicity and Safety of a China-made Monovalent Pandemic (H1N1) 2009 Influenza a Vaccine in Healthcare Workers in Guangzhou, China. Jpn J Infect Dis. 2011;64(3):190-4. PubMed PMID: 21617301.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunogenicity and safety of a China-made monovalent pandemic (H1N1) 2009 influenza A vaccine in healthcare workers in Guangzhou, China. AU - Zhan,Yangqing, AU - Yang,Zifeng, AU - Li,Lianna, AU - Ye,Dan, AU - Wu,Huiyan, AU - Fu,Renzhen, AU - Zhao,Suishan, AU - Wang,Yutao, AU - Zhou,Rong, AU - Chen,Rongchang, PY - 2011/5/28/entrez PY - 2011/5/28/pubmed PY - 2011/9/9/medline SP - 190 EP - 4 JF - Japanese journal of infectious diseases JO - Jpn J Infect Dis VL - 64 IS - 3 N2 - Because healthcare workers played an important role in the battle against novel pandemic (H1N1) 2009 influenza, a clinical study was conducted to examine the immunogenicity and safety of a single dose of a China-made monovalent, split-virus, pandemic (H1N1) 2009 influenza vaccine in this special high-risk population. Healthcare workers in the First Affiliated Hospital of Guangzhou Medical College who received the pandemic (H1N1) 2009 influenza vaccine were prospectively enrolled. Antibody titers were measured at enrollment and 14 days later using hemagglutination-inhibition (HI) and microneutralization assays. Adverse events were recorded within 7 days and 6 months after vaccination. Double sera were provided by 51 of 65 enrolled subjects. Postvaccination titers of 1:40 or more on HI assay were observed in 96% of recipients. Seroconversion or a significant increase in titer on HI assay occurred in 59% of subjects. The factor increase in GMTs was 4.3. The majority of complaints were mild to moderate in intensity. Although more than half of healthcare workers seemed immune to the pandemic (H1N1) influenza A virus before vaccination, most of the subjects still showed a fast, robust immune response to a single 15-μg dose of a monovalent, split-virus unadjuvanted pandemic H1N1 2009 influenza vaccine. SN - 1884-2836 UR - https://www.unboundmedicine.com/medline/citation/21617301/Immunogenicity_and_safety_of_a_China_made_monovalent_pandemic__H1N1__2009_influenza_A_vaccine_in_healthcare_workers_in_Guangzhou_China_ L2 - https://medlineplus.gov/flu.html DB - PRIME DP - Unbound Medicine ER -